People with the rare growth hormone disorder acromegaly have a significantly higher risk of developing various types of cancer, often at ages younger than typically seen in the general population, ...

Most adults with acromegaly reduced IGF-1 levels and improved acromegaly symptoms with once-monthly subcutaneous octreotide ...

The Palsonify-treated subjects maintained control, with stable growth hormone levels, symptom scores, and pituitary tumour ...

Patients with acromegaly make too much growth hormone, which causes them to grow disproportionately large bones, organs and ...

Global “Acromegaly and Gigantism Drugs Market” 2024 report of |83 Pages| focuses on the research which provides a market analysis using various analytical techniques, including Porter’s Five ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting ...

Despite a less than half effectiveness rate, acromegaly treatment typically starts with first-generation somatostatin receptor ligands (fgSRLs) as first-line drugs (octreotide or lanreotide ...

Acromegaly, sometimes referred to as gigantism, is a serious hormonal disorder caused by a benign tumor in the pituitary gland that secretes growth hormone. Over 25,000 patients in the U.S. suffer ...